Pulike Biological Engineering Asset Resilience Ratio
Pulike Biological Engineering asset resilience ratio. Pulike Biological Engineering (603566) has an Asset Resilience Ratio of 17.82% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Pulike Biological Engineering (603566) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pulike Biological Engineering (2015–2024)
Asset resilience ratio of Pulike Biological Engineering from 2015 to 2024. This chart shows how Pulike Biological Engineering's Asset Resilience Ratio has changed over time. Read 603566 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pulike Biological Engineering's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pulike Biological Engineering balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥550.97 Million | 17.82% |
| Total Liquid Assets | CN¥550.97 Million | 17.82% |
Asset Resilience Insights
- Good Liquidity Position: Pulike Biological Engineering maintains a healthy 17.82% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Pulike Biological Engineering Industry Peers by Asset Resilience Ratio
Compare Pulike Biological Engineering's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Pulike Biological Engineering Asset Resilience Ratio by Year (2015–2024)
Pulike Biological Engineering asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Pulike Biological Engineering.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.51% | CN¥480.33 Million ≈ $70.29 Million |
CN¥3.10 Billion ≈ $453.22 Million |
+3.01pp |
| 2023-12-31 | 12.49% | CN¥407.58 Million ≈ $59.64 Million |
CN¥3.26 Billion ≈ $477.36 Million |
-7.92pp |
| 2022-12-31 | 20.41% | CN¥691.36 Million ≈ $101.17 Million |
CN¥3.39 Billion ≈ $495.56 Million |
+16.96pp |
| 2021-12-31 | 3.46% | CN¥75.00 Million ≈ $10.97 Million |
CN¥2.17 Billion ≈ $317.29 Million |
-9.63pp |
| 2020-12-31 | 13.09% | CN¥265.48 Million ≈ $38.85 Million |
CN¥2.03 Billion ≈ $296.88 Million |
-3.45pp |
| 2019-12-31 | 16.53% | CN¥315.00 Million ≈ $46.09 Million |
CN¥1.91 Billion ≈ $278.83 Million |
+1.03pp |
| 2018-12-31 | 15.50% | CN¥295.00 Million ≈ $43.17 Million |
CN¥1.90 Billion ≈ $278.48 Million |
-23.29pp |
| 2017-12-31 | 38.79% | CN¥700.20 Million ≈ $102.46 Million |
CN¥1.81 Billion ≈ $264.14 Million |
+9.14pp |
| 2016-12-31 | 29.65% | CN¥515.00 Million ≈ $75.36 Million |
CN¥1.74 Billion ≈ $254.15 Million |
+3.05pp |
| 2015-12-31 | 26.60% | CN¥400.00 Million ≈ $58.53 Million |
CN¥1.50 Billion ≈ $220.04 Million |
-- |
About Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.